Company Registration No. 32266355
Copenhagen, Denmark, September 19, 2022 – Orphazyme A/S (ORPHA.CO) (the “Company”) announces an update to the Company’s financial calendar in regard to the publication of the Company’s Interim Report First Half 2022. The Interim Report First Half 2022 will be published on September 26, 2022, previously September 20, 2022. Additional time is required to conclude the presentation of the financial statements following the sale of substantially all Orphazyme’s assets and business activities to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm, Inc. (KMPH: NASDAQ, NY) which completed during the reporting period.
Interim Report First Half 2022
September 26, 2022
For additional information, please contact
Anders Vadsholt, Chief Executive Officer and Chief Financial Officer +45 28 98 90 55